NasdaqGS:INCYBiotechs
First Chemotherapy-Free CD19/CD20 Lymphoma Regimen In Europe Might Change The Case For Investing In Incyte (INCY)
In mid-December 2025, Incyte announced that the European Commission approved Minjuvi (tafasitamab) with lenalidomide and rituximab for adults with relapsed or refractory Grade 1–3a follicular lymphoma after at least one prior systemic therapy.
This creates the first approved CD19/ CD20 dual-targeted, chemotherapy-free immunotherapy regimen for eligible follicular lymphoma patients in Europe, meaningfully broadening Incyte’s oncology footprint in a key market.
We’ll now examine how this new...